ICU Medical, Inc. (ICUI) Tops Q2 EPS by 4c; Narrows FY12 Outlook
Tweet Send to a FriendGet Alerts ICUI Hot Sheet
Price: $67.54 +0.61%
EPS Growth %: +9.4%
Financial Fact:
Selling, general and administrative: 22.87M
Today's EPS Names:
LBIX, ESEA, ISS, More
EPS Growth %: +9.4%
Financial Fact:
Selling, general and administrative: 22.87M
Today's EPS Names:
LBIX, ESEA, ISS, More
Trade ICUI Now!
ICU Medical, Inc. (NASDAQ: ICUI) reported Q2 EPS of $0.63, $0.04 better than the analyst estimate of $0.59. Revenue for the quarter came in at $77.3 million versus the consensus estimate of $77.98 million.
ICU Medical, Inc. sees FY2012 EPS of $2.55-$2.70, versus prior guidance of $2.45-$2.70 and the consensus of $2.58. ICU Medical, Inc. sees FY2012 revenue of $318-$325 million, versus prior guidance of $318-$330 million and the consensus of $321.3 million.
For earnings history and earnings-related data on ICU Medical, Inc. (ICUI) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
ICU Medical, Inc. sees FY2012 EPS of $2.55-$2.70, versus prior guidance of $2.45-$2.70 and the consensus of $2.58. ICU Medical, Inc. sees FY2012 revenue of $318-$325 million, versus prior guidance of $318-$330 million and the consensus of $321.3 million.
For earnings history and earnings-related data on ICU Medical, Inc. (ICUI) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
- Agilent (A) Tops Q2 EPS by 9c, Trims FY13 Outlook; Adds to Buyback, Will Cut Jobs
- 21Vianet Group (VNET) Misses Q1 EPS by 4c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

